,0
symbol,RVMD
price,39.5
beta,0.0
volAvg,451181
mktCap,2604096770
lastDiv,0.0
range,17.345-47.14
changes,1.46
companyName,Revolution Medicines Inc
currency,USD
cik,0001628171
isin,US76155X1000
cusip,76155X100
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://revolutionmedicines.com/
description,"Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Companyâ€™s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity."
ceo,"Dr. Mark A. Goldsmith M.D., Ph.D."
sector,Healthcare
country,US
fullTimeEmployees,95
phone,14157663638
address,700 Saginaw Dr
city,Redwood City
state,CALIFORNIA
zip,94063
dcfDiff,
dcf,
image,https://financialmodelingprep.com/image-stock/RVMD.jpg
ipoDate,2020-02-13
defaultImage,True
